Terms: = Kidney tumors AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED
106 results:
1. Gain-of-function mycn causes a megalencephaly-polydactyly syndrome manifesting mirror phenotypes of Feingold syndrome.
Nishio Y; Kato K; Tran Mau-Them F; Futagawa H; Quélin C; Masuda S; Vitobello A; Otsuji S; Shawki HH; Oishi H; Thauvin-Robinet C; Takenouchi T; Kosaki K; Takahashi Y; Saitoh S
HGG Adv; 2023 Oct; 4(4):100238. PubMed ID: 37710961
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic Utility of GATA3 and ISL1 in Differentiating Neuroblastoma From Other Pediatric Malignant Small Round Blue Cell tumors.
Mohanty SK; Diwaker P; Mishra SK; Jha S; Lobo A; Panda SP; Sharma S; Kumar M; Arora S; Mallik V; Jain D; Jain E; Chakrabarti I; Varshney J; Beg A; Dixit M; Baisakh MR; Naik S; Sahoo SK; Akgul M; Balzer BL; Amin MB; Parwani AV
Int J Surg Pathol; 2024 Apr; 32(2):294-303. PubMed ID: 37312579
[TBL] [Abstract] [Full Text] [Related]
3. Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression.
Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Wu R; Dennison JB; Peterson CB; Zhao H; Do KA; Halperin DM; Agarwal SK; Blau JE; Jha S; Rivero JD; Nilubol N; Walter MF; Welch JM; Weinstein LS; Vriens MR; van Leeuwaarde RS; van Treijen MJC; Valk GD; Perrier ND; Hanash SM; Katayama H
J Clin Endocrinol Metab; 2023 Nov; 108(12):3260-3271. PubMed ID: 37307230
[TBL] [Abstract] [Full Text] [Related]
4. mTOR Regulation of n-myc Downstream Regulated 1 (NDRG1) Phosphorylation in Clear Cell Renal Cell Carcinoma.
Valluri A; Wellman J; McCallister CL; Brown KC; Lawrence L; Russell R; Jensen J; Denvir J; Valentovic MA; Denning KL; Salisbury TB
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298315
[TBL] [Abstract] [Full Text] [Related]
5. CHRM4/AKT/mycn upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer.
Wen YC; Tram VTN; Chen WH; Li CH; Yeh HL; Thuy Dung PV; Jiang KC; Li HR; Huang J; Hsiao M; Chen WY; Liu YN
Cell Death Dis; 2023 May; 14(5):304. PubMed ID: 37142586
[TBL] [Abstract] [Full Text] [Related]
6. Targeting PKLR/mycn/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
[TBL] [Abstract] [Full Text] [Related]
7. WNT1 Inducible Signaling Pathway Protein 1 Is a Stroma-Specific Secreting Protein Inducing a Fibroblast Contraction and Carcinoma Cell Growth in the Human Prostate.
Chang KS; Chen ST; Sung HC; Hsu SY; Lin WY; Hou CP; Lin YH; Feng TH; Tsui KH; Juang HH
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232736
[TBL] [Abstract] [Full Text] [Related]
8. The immune landscape of solid pediatric tumors.
Sherif S; Roelands J; Mifsud W; Ahmed EI; Raynaud CM; Rinchai D; Sathappan A; Maaz A; Saleh A; Ozer E; Fakhro KA; Mifsud B; Thorsson V; Bedognetti D; Hendrickx WRL
J Exp Clin Cancer Res; 2022 Jun; 41(1):199. PubMed ID: 35690832
[TBL] [Abstract] [Full Text] [Related]
9. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
[TBL] [Abstract] [Full Text] [Related]
10. A Novel Inflammation-Related Gene Signature for Overall Survival Prediction and Comprehensive Analysis in Pediatric Patients with Wilms Tumor.
Zhang J; Lai Y; Zhu L; Lu Z; Hu C; Zhou H; Lu Z; Tang Z; He Z; Tang F
Dis Markers; 2022; 2022():2651105. PubMed ID: 35578692
[TBL] [Abstract] [Full Text] [Related]
11. Relapses Rates and Patterns for Pathological T0 After Robot-Assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium.
Elsayed AS; Iqbal U; Jing Z; Houenstein HA; Wijburg C; Wiklund P; Kim E; Stöckle M; Kelly J; Dasgupta P; Wagner AA; Kaouk J; Badani KK; Redorta JP; Mottrie A; Peabody JO; Rouprêt M; Balbay D; Richstone L; Rha KH; Aboumohamed A; Li Q; Hussein AA; Guru KA
Urology; 2022 Aug; 166():177-181. PubMed ID: 35461914
[TBL] [Abstract] [Full Text] [Related]
12. Bromodomain 4 inhibition leads to mycn downregulation in Wilms tumor.
Woods AD; Berlow NE; Ortiz MV; Dela Cruz F; Siddiquee A; Coutinho DF; Purohit R; Freier KET; Michalek JE; Lathara M; Matlock K; Srivivasa G; Royer-Pokora B; Veselska R; Kung AL; Keller C
Pediatr Blood Cancer; 2022 Feb; 69(2):e29401. PubMed ID: 34693628
[TBL] [Abstract] [Full Text] [Related]
13. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
Schultz CR; Swanson MA; Dowling TC; Bachmann AS
Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
[TBL] [Abstract] [Full Text] [Related]
14. Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
Valind A; Gisselsson D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1397. PubMed ID: 33932141
[TBL] [Abstract] [Full Text] [Related]
15. LncRNA NORAD stimulates proliferation and migration of renal cancer via activating the miR-144-3p/mycn axis.
Zhao W; Wang L; Xu F
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10426-10432. PubMed ID: 33155199
[TBL] [Abstract] [Full Text] [Related]
16. Hypoxia-responsive miR-346 promotes proliferation, migration, and invasion of renal cell carcinoma cells via targeting NDRG2.
Su ZH; Liao HH; Lu KE; Chi Z; Qiu ZQ; Jiang JM; Wu Z
Neoplasma; 2020 Sep; 67(5):1002-1011. PubMed ID: 32453597
[TBL] [Abstract] [Full Text] [Related]
17. Copy Number Variations in Wilms Tumor: A Pilot Study From India.
Rahiman EA; Singh M; Bhatia P; Kakkar N; Trehan A; Bansal D
J Pediatr Hematol Oncol; 2020 Jul; 42(5):e299-e304. PubMed ID: 31851072
[TBL] [Abstract] [Full Text] [Related]
18. The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.
Li X; Hou G; Zhu Z; Yan F; Wang F; Wei D; Zheng Y; Yuan J; Zheng W; Zhang G; Meng P; Guo Y; Li X; Yao L; Shen L; Yuan J
Invest New Drugs; 2020 Aug; 38(4):956-966. PubMed ID: 31463638
[TBL] [Abstract] [Full Text] [Related]
19. mycn gene polymorphisms and Wilms tumor susceptibility in Chinese children.
Huang X; Zhao J; Zhu J; Chen S; Fu W; Tian X; Lou S; Ruan J; He J; Zhou H
J Clin Lab Anal; 2019 Nov; 33(9):e22988. PubMed ID: 31343784
[TBL] [Abstract] [Full Text] [Related]
20. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
[TBL] [Abstract] [Full Text] [Related]
[Next]
